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Background: There are few, recent, well assessed, multiple sclerosis (MS) incidence surveys on European populations.
This study sought to measure MS incidence in a Northern Lisbon population and assess it using capture-recapture
methods (CRMs).
Methods: Among the population residing in the Northern Lisbon Health Area, registered MS diagnoses were obtained
from general practitioners in three primary-care districts covering a population of 196,300, and a neurology unit at the
main referral hospital. Cases with onset during the periods 1978–1997 and 2008–2012 were excluded due to perceived
poor access to image-supported neurological diagnosis and administrative changes in patient referral respectively.
Age- and sex-specific incidences for the period 1998–2007 were calculated using McDonald diagnostic criteria,
and CRMs were used to correct age-specific incidence rates. The corrected figures were also adjusted for age
using the European Standard Population as reference.
Results: When applied to 62 MS patients with onset in the period 1998–2007, the rates per 100,000 population were
as follows for both sexes: crude, 3.16; age-adjusted, 3.09 (95% CI 2.32 to 3.87); CRM-adjusted, 4.53 (95% CI 3.13 to 5.94);
and age- and CRM-adjusted, 4.48 (3.54-5.41). In general, the rates were 3-fold higher among women than among
men. Negative source dependency and CRM impact were highest at ages 35–44 years, where a 60% rise led to a
peak incidence.
Conclusions: MS incidence in Northern Lisbon, Portugal, is moderately lower than that yielded by surveys on
European populations. CRMs, which in this instance suggest undercounts, are a potentially useful tool for
case-finding assessment but their application may introduce bias.
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The incidence of multiple sclerosis (MS) in Portuguese
populations is not known. Prior reports on the occur-
rence of MS in these populations have been limited to
prevalence studies [1]. A recent review of MS incidence
surveys conducted in the European Economic Area in
the period 1985–2009 revealed that, after 1985, MS inci-
dence ranged from just over 1 to almost 7 per 100,000
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Some observations [3,4] suggest that MS incidence in
southern Europe, i.e., in Catania 2000–2004 and San
Marino 1990–2005, may have reached or even exceeded
the magnitude seen for northern European populations.
Changes in diagnostic criteria –which are broader now
than in the past–, the growing role of neurologists in the
management of the disease, the use of more specific la-
boratory and imaging techniques, and the application of
new therapeutic tools, unknown until only just a few
years ago, may have all contributed to a keener aware-
ness of the disease among health-care workers and pa-
tients alike.
The capture-recapture method (CRM) is a classic pro-
cedure intended to estimate prevalence or incidence, byhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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where cases are collected from different sources [5,6].
The results of applying CRMs to MS prevalence have
been reported by seven studies, in every case based on
crude prevalence counts [7-13], and show that increases
in prevalence estimates vis-à-vis uncorrected figures are
high, rising to 38% in a recent Spanish study [12]. Al-
though capture-recapture methods have hardly been ap-
plied to MS incidence, two studies [13,14] have shown
CRMs effects to be stronger, leading to 47.3% and 80%
increments in crude incidences respectively.
Hook and Regal have stressed the importance of valid-
ating CRMs using "real" data instead of simulated infor-
mation [15], and recently Jones et al. reported problems
in applying CRM to surveys where there had been
underlying referral of patients between sources [16]. We
explored the feasibility of applying CRM, using age-
specific incident MS samples and selecting methodo-
logical options deemed to be appropriate for the disease
where populations differ in age-structure [17,18]. In sum,
CRMs are increasingly used in MS surveys and their im-
pact on measurements is high. However, MS researchers
might not have been fully aware of major CRM flaws. Ac-
cordingly, this study sought to assess MS incidence in a
Portuguese population and apply CRMs to the incidence
sample.
Methods
Study populations and medical services
We studied MS incidence during a specific period among
the resident catchment population of three, geographic-








Figure 1 Geographical location of study populations within the NorthHealth Area, i.e., Benfica, Pontinha and Odivelas, which
account for an overall, socially mixed population of
196,300, made up of a working-class stratum in Pontinha
and middle- and upper-class strata in part of Odivelas
and Benfica. These subpopulations are traditionally served
by the Santa Maria Hospital (SMH), which also provides
neurological care to a population of more than double the
size. The geographical situation of the catchment areas of
the above three primary-care districts in the early years of
this century and the location of the SMH are depicted in
Figure 1. In terms of quality, this population's access to
neurology specialists matches that described for other
urban Portuguese populations.
Neurological care in Portugal, with one neurologist
per approximately 30,000 inhabitants, is provided by the
country's public National Health Service (NHS), special
social health insurance schemes for certain professions
(health subsystems), and voluntary private health insur-
ance (see de Sá et al. [18] for details). In Portugal, primary
care is provided at NHS primary-care centres (PCCs), with
each centre generally serving the catchment population
residing in the geographical area in which it is located. As
the cost of MS treatment is wholly subsidised by the NHS,
MS patients are required to be registered at the health
centres in their respective residential areas. Insofar as the
study populations were concerned, Lisbon's SMH, where
this study's principal researcher (JS) practices, has been
the main referral centre for their designated regional health
area for decades.
The ongoing economic crisis, which has been in
evidence since the mid-2000s, has had an impact on
the Portuguese health care administration, potentiallyern Lisbon area.
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tals, MS diagnosis, and the availability of data for apply-
ing McDonald diagnostic criteria, which encompass
cranial magnetic resonance imaging (MRI). Firstly, the
delay in performing a cranial MRI at the SMH, which
was approximately one year in the mid-2000s, has inevit-
ably increased since 2008 as a result of general re-
strictions on performing MRI studies at public health
facilities and this, in turn, has resulted in an important
delay in MS diagnosis for patients with recent onset. Sec-
ondly, in April 2007 a large private hospital was opened
in the Northern Lisbon geographical area. It was created
to serve patients with private insurance and private
health systems. Thirdly, general practitioner (GP) units
were also targeted for change: Family Health Units
(Unidades de Saúde Familiares) were private administra-
tive units created towards the end of 2008 and co-existed
alongside the traditional primary care units in the field,
such as those in Odivelas, Benfica and Pontinha. This
implicated a redistribution of local GPs and, though it
did not modify the study population, communication be-
tween the publicly-run hospital units, such as the SMH,
and these new units may have differed from that which
had existed with the traditional PCCs. Fourthly, in 2011 a
mixed public/private unit staffed by seven neurologists
was set up in Loures, and has since become the reference
unit for patients from the Odivelas and Pontinha PCCs.
Traditionally, national regulations in Portugal confer a
limited capacity on neurologists and other clinicians to
provide immunomodulatory treatments to MS patients,
in cases where MS patients are not referred to a publicly-
run hospital.
Diagnostic criteria, case-finding and outcome of
epidemiological classification
The project was approved by the SMH Research Ethics
Committee in 2007. All persons gave their informed
consent to JS prior to their inclusion in the incidence
study.
Diagnostic criteria
Only patients ever fulfilling McDonald 2001 MS diag-
nostic criteria [19] were included in the case series
resulting from case-finding and are referred to as "MS
patients". Patients suspected of suffering from MS but
still undergoing clinical evaluation or having symptoms
difficult to interpret, were not included in the database.
Patients fulfilling McDonald criteria for clinically iso-
lated syndrome at their most recent neurological visit
were excluded.
Case finding
A case search was independently conducted at two sources,
namely, PCCs and the SMH.Primary-care-based case search
In 2009, all PCCs in Lisbon's Northern Health Area were
invited to participate in this survey. After the directors
of the Benfica, Pontinha and Odivelas PCCs presented
the project to their staff, all three volunteered to partici-
pate. During several meetings with a neurologist field re-
searcher at the three PCCs, GPs received instructions
and criteria for identifying patients suffering from MS,
i.e., patients were required to present with diagnosis of
MS established by a department of neurology or a local
neurologist. The GPs agreed to participate and complete a
spreadsheet with patient data. At each centre, the Director
appointed a local researcher to implement data-collection.
All the GPs −57 in Odivelas, 13 in Pontinha and 36 in
Benfica- collaborated. Field data-collection at the three
centres was undertaken in the period September 2009 to
December 2010 and updated in December 2012 to cover
cases with potential diagnostic delay. When GP data were
furnished to the research team for the purpose of applying
diagnostic criteria, JS contacted patients' neurologists
who were active at the facilities where the MS diag-
noses known to the GPs had been made: these comprised
private neurologists reporting to the three PCCs (ten cases)
and neurologists serving at publicly-run neurological de-
partments at Lisbon hospitals (i.e., the Capuchos and Egas
Moniz Hospitals, eight and five patients respectively). After
examining 25 case records, JS excluded five patients for
different reasons: three for not fulfilling diagnostic criteria
due to dissemination-in-time requirements; and two others
for having conditions other than MS (one with MRI lesions
not typical for MS, and the other with isolated myelitis
with normal cranial MRI).
Search based at the Santa Maria Hospital
During the study period, the database of patients diag-
nosed with MS at the SMH unit directed by JS was ex-
plored in order to identify residents in the above three
primary-care districts. In addition, a few patients with
MS but not shown on the GP lists were identified by JS
after a request for information had been sent to neurolo-
gists in private practice. Patients were labelled as being
known or unknown to the GPs, firstly by reason of the
fact that their names were absent from the respective
GP's list, and secondly on confirmation at the above-
mentioned meetings of the fact that there was no record
of MS diagnosis in the patient's clinical history at the
PCC. JS examined the neurology records of patients at-
tending the SMH and applied diagnostic criteria at the
end of 2010 and again at the end of 2012.
Choice of incidence study period and ascertainment of
residence at clinical onset
Once the PCC and SMH case-finding had been deemed
to be complete, the diagnostic criteria applied and the
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of MS onsets was then tabulated for 112 MS patients and
plotted for 106 with known year of and age at clinical onsetTable 1 Case-finding and distribution of cases fulfilling McDo
clinical onset
Calendar year Age groups
0-14 15-24 25-34 35-44





















1998 1 1 1
1999 2 1 5
2000 1 1 2
2001 3 1 2
2002 1 2 1 3
2003 1 1 2 1
2004 1 1 1 1 1
2005 1 1 3








Total 1 10 10 8 24 8 34
M indicates men; W indicates women.(see Table 1 and Figure 2). Completion of case-finding by
contact with clinicians or managers at the above private
facilities which had come into existence since 2008 wasnald diagnostic criteria by age group, sex and year of
45-54 55-64 65+ Unknown Total
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Figure 2 Outcome of case-finding by year of onset and diagnosis. Annual number of multiple sclerosis onsets or multiple sclerosis
diagnoses for 106 cases fulfilling diagnostic criteria among the pooled population from 1978 to 2012. The study period, 1998–2007, is marked
between vertical dash-dotted lines.
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the case-finding outcome determined the selection of
the survey incidence period as the ten-year interval from
1998 to 2007. The reason was that potential patients
with onsets in this period were regarded as having the
highest probability of undergoing an MRI study (which
became standard practice from 1998 onwards, coincid-
ing with the opening of a specific MS unit at the HSM)
and being identified by the case-finding strategy. All
MS patients with clinical onset across the period 1998–
2007 and listed in Table 1 presented with their first MS
symptoms while residing in the catchment area of one
of the three PCC districts, as verified from GPs' admin-
istrative documents, SMH records or both. An outline
of the participant flow from case-finding to becoming
MS incidence patients included in the study is shown
in Figure 3.
Denominators of incidence counts
For the purpose of generating age-specific populations
close to the mid-point of the incidence period, we ob-
tained age-specific 2001 census populations for admin-
istrative units that overlapped the residential areas of
primary-care users (i.e., those of the Benfica and Pontinha
parishes and the Odivelas municipal area) and yielded
a reasonable fit with primary-care districts of the same
name (here denoted as the "Northern Lisbon Districts
population"). Male and female catchment populations for
each of the above-mentioned PCCs in the mid-2000s
were obtained from the health authorities, and estimates
of age and sex distributions were drawn up using the
above-mentioned 2001 census data. The distributions of
each of the three health-district populations by age and sex
are shown in Table 2.Capture-recapture methodology
Data-source design
In accordance with early procedural suggestions [6,20],
patient identification was followed by distinguishing
three "original" sources, namely, the SMH, three GP
lists at PCCs, and some private practitioners; and two
"analytical" sources, the SMH and PCCs, used for CRM
calculations, after private practitioners and GPs at PCCs
had been pooled into one source. Independence of data
sources was verified by testing the statistical significance
of deviations between the expected and observed distri-
bution of cases at the SMH and PCC intersect on a 2×2
table, obtained from product probabilities of the main
analytical subsets and shown in Figure 4.
Calculations for CRM
We proceeded as summarised in Figure 5, assuming
source independence on the basis of reported methods
[6,21-24]. CRM-corrected incidence estimates and their
95% confidence intervals (CIs) were obtained for pooled
populations at all ages and by age-specific strata. To re-
capitulate, the CRM-corrected incidence numerator was
generated with the Sekar and Deming method [21], as
modified by Chapman [22] and Seber [23], using the
procedure described in Hook and Regal [15] and termed
the Chapman nearly unbiased estimator (NUE), which is
shown in Figure 5 with an example for all districts
across all ages. The estimated value for the unobserved
cell was obtained, as indicated in Figure 5, from the
rounded Chapman NUE figure minus the three ob-
served cell numbers. The 95% confidence interval (CI)
of CRM-corrected incidence was obtained from 95%
limits for the CRM-corrected value, by using the proced-


















Repeated records at different sources
n=28




Not fulfilling McDonald criteria
n=5
Figure 3 Study participant flow chart.
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[25,26] (Figure 5). Finally, CRM-corrected and -uncorrected
incidence figures and 95% CIs were age-adjusted by the
direct method, in order to compare them to virtual rates
from a standard population. We used European Standard
Population weights provided by Zivadinov et al. [17]
for MS incidence strata [17], and the Epidat 3.1 soft-
ware procedure (Galician Regional Authority, Santiago deTable 2 Average population and time at risk during incidence
crude and adjusted incidence rates
Person-years Cases
Age group Men Women Total Men Wome
0-14 134,440 128,500 262,940 0 0
15-24 143,300 138,040 281,340 5 8
25-34 154,460 149,600 304,060 4 11
35-44 124,980 133,820 258,800 4 21
45-54 136,010 158,730 294,740 0 6
55-64 127,850 140,930 268,780 0 2
65+ 119,570 172,890 292,460 0 1
All ages 940,610 1,022,510 1,963,120 13 49
Adjusted rates
aAge-adjusted and bage-and sex-adjusted (European population) with their correspCompostela, Spain/Pan American Health Organisation,
Washington, D.C, 2005) for direct adjustment.
Completeness
Heterogeneity of completeness (captured proportion of
estimated cases, i.e., ratio of cases detected by a given
source to total estimated cases) was tested using the
χ2 test for 2×2 or 2×n contingency tables.period (1998–2007), as well as age-specific and overall
Incidence rates
n Total Men Women Total
0 0.00 0.00 0.00
13 3.49 5.80 4.62
15 2.59 7.35 4.93
25 3.20 15.69 9.66
6 0.00 3.78 2.04
2 0.00 1.42 0.74
1 0.00 0.58 0.34
62 1.38 4.79 3.16
1.30 (0.59-2.01)a 4.79 (3.44-6.13)a 3.09 (2.32-3.87)b







































Figure 5 Calculation of correction by recapture, completeness and so
















Figure 4 Distribution of multiple sclerosis patients with
onset in the period 1998–2007, by main source, primary-care
district (Odivelas, Benfica and Pontinha) and SMH, Santa
Maria Hospital.
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For the purposes of interpreting results, the age-specific
MS incidence in Northern Lisbon, both CRM-corrected
and -uncorrected, was compared to age-specific MS in-
cidence as reported by three, recent, selected surveys
that were undertaken in Catania (Italy) [4], Lorraine
(France) [27] and Västerbotten (Sweden) [28] using the
less sensitive Poser clinical or clinical and laboratory
supported criteria for probable MS [2].
Results
As briefly mentioned under Methods, after detailed exam-
ination of neurology records kept by the SMH and a few
specialists (mostly neurologists) contacted by GPs and JS,
62 patients were found to fulfil McDonald 2001 criteria for
MS, with clinical onset during the period 1998–2007 and
residence in Northern Lisbon's three PCC districts.
The 62 MS patients classified by source, original or
analytical, are depicted in Figure 4. Balance by origin
was in evidence, with 24 cases seen exclusively at the
SMH, 23 seen exclusively at PCCs and 15 seen at both
sources. During the period 1998–2007, overall crude in-
cidence (Table 3) was 3.16 and age-and sex-adjusted in-
cidence was 3.09 per 100,000 person-years (95% CI 2.32
to 3.87). Crude and age-adjusted MS incidence per
100,000 person-years was 1.38 and 1.30 (95% CI 0.59-































urce dependency on multiple sclerosis incident patients during
ria Hospital; and S, sensitivity (or completeness).
Table 3 Age distribution of incident MS patients for 1998–2007: observed cases (OC) and estimated cases (EC) as well
as percentage of completeness
No. of patients Incidence rates per 100,000
OC Completeness% Crude Ascertainment corrected
SMH GP Both EC Total SMH GP Both Chapman
correction
Crude Ascertainment corrected Age-adjusted point
Point with 95% CI with 95% CIAge group Person-years
0-14 262,940 0 0 0 - - - - - 0.000 0.00 - -
15-24 281,340 6 3 4 3 16 62.5 43.8 81.3 16.600 4.62 5.69 (3.42-7.95) -
25-34 304,060 4 6 5 4 19 47.4 57.9 78.9 19.000 4.93 6.25 (4.07-8.43) -
35-44 258,800 13 7 5 15 40 45.0 30.0 62.5 40.167 9.66 15.46 (8.30-22.61) -
45-54 294,740 1 5 0 5 11 9.1 45.5 54.5 11.000 2.04 3.73 (0.09-7.37) -
55-64 268,780 0 1 1 0 2 50.0 100.0 100.0 2.000 0.74 0.74 (0.74-0.74) -
65+ 292,460 0 1 0 0 1 0.0 100.0 100.0 1.000 0.34 0.34 (0.34-0.34) -
All ages 1,963,120 24 23 15 27 89 43.8 42.7 69.7 89.767 3.16a 4.53 (3.13-5.94)b 4.48 (3.54-5.41)d
All districts 1,963,120 24 23 15 34 96 40.6 39.6 64.6 96.500 3.16a 4.89 (3.49-6.29)c -
MS: multiple sclerosis; OC: observed cases; EC: estimated cases; SMH: Santa Maria Hospital; GP: general practitioners; CI: confidence interval.
aCrude estimates; bascertainment-corrected incidence obtained from added age-specific N = 89 estimates; cascertainment-corrected incidence obtained from crude
N = 96 estimates; dpopulation age-adjusted and capture-recapture corrected rates.
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patients, crude MS incidence per 100,000 person-years
was 1.94, and when calculated for 39 SMH patients it
was similar, namely, 1.99 (data not shown in table), and
considerably lower than two-source incidence. Peak
values for age-specific figures were seen at ages 35–44
years, with the figure for both sexes being 9.66 per
100,000 person years and that for women being 15.69,
based on 21 cases; the figures for men were unstable,
though no cases started after the age of 44 years. Based
on the figures shown in Figure 5 and Table 3, in which
the data are broken down by age and source, the CRM-
corrected number of cases (N) was 96. Completeness
(Figure 5) for SMH and PCCs across all ages was 40.6%
and 39.6% respectively, rising to 64.6% for both sources
combined. Source probability for SMH and PCCs across
all ages was 0.63 and 0.61 respectively. The expected
intersect, 0.63 × 0.61 = 0.39, was higher than the ob-
served intersect 15/62 = 0.24, with the dependency
sign (0.24-0.39 < 0) thus being negative. Observed vs. ex-
pected numbers at the intersect, 15 vs. 24, and outside the
intersect, 47 vs. 38, yielded an odds ratio = 0.50 (95% CI
0.21 to 1.17).
Shown in two sections, upper and lower, in Table 3 is
the 2×2 breakdown of the two-source model when ap-
plied to nine observations, seven of which correspond to
horizontally aligned age-specific strata for pooled dis-
tricts (upper), and two of which correspond to the
pooled districts across all ages (bottom). The second last
row contains totals for all ages from vertically aligned
age-strata. The body of the table is divided into a left
block with cases and completeness results, and a rightblock with incidence figures, showing crude, age-specific,
uncorrected or CRM-corrected, and age- and CRM-
adjusted estimates.
The left block of Table 3 shows both the observed data
and the rounded Chapman NUE numbers, which was
89.8 for all districts at all ages, and ranged from one for
the 65-and-over to 40 for the 35–44 group on an age-
specific basis. When NUE estimates for age groups were
added, the rounded number, namely, 90, was 7% lower
than the figure of 96 obtained when the method was
applied to crude pooled populations. While the CRM-
estimated number of patients at ages ≥65 years was low,
i.e., one, it exceeded 40 in the 35–44 age group. Com-
pleteness for two sources and all ages was 64.6%. Two-
source completeness for age-specific groups was >78%,
except for the 35–44 and 45–54 age groups, but did not
prove significantly heterogeneous, with Fisher's exact
test p = 0.441, Pearson χ25 ¼ 5:258.
Incidence per 100,000 person-years in age-groups shown
in Table 3 (bottom right) displayed a considerably wide
variation, ranging, after correction for ascertainment, from
0.34 at age 65 years and over to 15.46 at ages 35–44 years.
CRM impact was highest for the 35–44 age group, increas-
ing from an observed 9.66 per 100,000 person-years to a
CRM-adjusted 15.46 per 100,000 person-years, i.e., by 60%.
Incidence at ages 45–54 years and over compared to that
at ages 30–44 years was low, but the CRM impact among
the 45–54 age group was non-negligible, i.e., 83%, based
on small numbers, and nil at ages 55 years and over, with a
limited effect on overall CRM impact in the age-adjusted
measurements. Finally, a complete overview of MS inci-
dence is shown in Table 3, for which crude observed
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after CRM correction to 4.53 per 100,000 person-years, i.e.,
by 43%, and after additional age-adjustment to 4.48 per
100,000 person-years, i.e., by 42%.
Figure 6 depicts age-specific MS incidence in Northern
Lisbon, both CRM-corrected and -uncorrected, as well
as the same reported rates in Catania [4], Lorraine [27]
and Västerbotten [28]. With regard to the uncorrected
figures, it would appear that considerably lower rates
were seen for the 25–34 year age-group, with those for
the other age groups being moderately lower. CRM-
corrected incidence at ages 35–44 years exceeded that
reported by other surveys.
Discussion
In addition to providing detailed figures of MS incidence
in a Northern Lisbon population, which is similar to or
moderately lower than that in other European popula-
tions, this study shows that age- and CRM-adjustment
considerably modify crude figures, that the impact of
CRM adjustment can be age-specific, and that adjust-
ment for age has a small impact, given the coincidence
of the age structure of the European Standard and
Portuguese study populations.
A key question to be answered is the validity of our
CRM-corrected measurements and the significance of
CRM. Capture-recapture methods have been widely dis-
cussed and some authors have suggested a need for cau-
tion when using them in epidemiology [16,29-32]. In
contrast to expected CRM results, namely, that most data
sets used by epidemiologists tend to have a net positive
dependence [15], our results suggest that the source de-
pendency present in our study was negative, and highest
for the 35–44 age-group, something that would tend
to produce CRM-corrected incidence overestimates andFigure 6 Age-specific multiple sclerosis incidences reported for select
after capture-recapture correction. CRM indicates capture-recapture metthereby reduce the validity of the application [6]. Negative
dependency, namely, a situation in which the proportion of
cases known both to the SMH and PCCs is too low, applies
here because the number of cases, 15, captured by the
SMH and PCC intersect is too low compared to the ex-
pected proportion of 39%, i.e., 24 cases. According to our
expectations, and contrary to what was anticipated by
Jones et al. [16] in the presence of referrals between
sources, the positive dependency due to the fact that pa-
tients with MS attending PCCs have historically tended to
be diagnosed at the SMH as a result of traditional referral
policies and geographical proximity, was neutralised or
even reversed. We believe that negative dependency in our
series might point to unnoticed losses in case-finding of
MS patients who, rather than being sourced at the
SMH as expected, were instead missing. Negative de-
pendence was highest in the 35–44 age group, which is
difficult to explain. All things considered, CRM-corrected
results would seem to be overestimated, while uncorrected
results, in contrast, might constitute underestimates
because of limited case finding. We believe that the
most accurate and valid measurement of MS incidence
in the Northern Lisbon Districts population is closer to
the CRM-uncorrected age-specific measurements, thus
reinforcing the notion of similar or moderately lower
incidences.
For comparisons between surveys, our uncorrected mea-
surements point to incidences at ages <24 and >35 years
which are almost similar to those of the Catania, Lorraine
and Västerbotten studies, whereas incidences at 25–34
years are atypically lower than expected. Assuming that
MS incidence in Portugal behaves as in other northern or
southern European populations, among whom incidence
peaks in the 25–34 age-group [2], the notions of a switch
from age-at-onset towards age-at-diagnosis in our survey,ed surveys, including those seen in Northern Lisbon before and
hod.
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care, would also have to be considered. The Catania,
Lorraine and Västerbotten studies used Poser diag-
nostic criteria, which included laboratory supported cri-
teria (perhaps 20% more sensitive) in the case of Catania
and Västerbotten. McDonald criteria established MRI
as the standard for capturing disease dissemination [33],
enabling a definite MS diagnosis to be established
12 months earlier where a cranial MRI disclosed a new
T2 lesion, as shown by Tintoré et al. [34]. It would thus
appear that part of the difference between selected sur-
veys could be attributed to diagnostic criteria, and that
the difference in incidences with respect to the Lisbon
survey was masked by use of more sensitive diagnostic
criteria. The expected effect of the midpoint of the inci-
dence period on differences is difficult to assess. When
using a model fitted in a prior study [2] with adjustment
for age and sex, our CRM uncorrected incidence shows a
lower rate ratio (0.55 with a 95% CI 0.40-0.74) than that
in Lorraine, together with an absence of significant differ-
ences when compared to those in Västerbotten, Catania
and our CRM-corrected incidences, yielding a rate ratio
of 0.77 (and a 95% CI 0.59-1.01) for the latter. These
figures may support a dominant negative bias effect of
limited case finding which would prevail over the positive
effect of diagnostic criteria. The long duration of the
period 2008–2012 affords protection against the effect of
diagnostic delay [35], with our overall incidence thus be-
ing only moderately lower than in other French, Italian
or Nordic populations.
New health policies introduced in Portugal as from
2008 led to changes in referral from the study areas to
publicly-run hospitals. This prevented accurate ascer-
tainment of any incident cases occurring after that date,
and so our study had to be limited to the period from
1998 to 2007. Potential incomplete ascertainment of in-
cident cases during the period 1998–2007 might thus
have occurred. One cannot rule out the possibility that a
few patients might have moved away from the desig-
nated study districts after MS onset and, as a result,
would not appear on the collaborating GPs' lists. Simi-
larly, patients with mild MS symptoms may not have
sought after-care or been referred to neurologists. Fur-
thermore, some patients residing in the study region
could have been attended by doctors from other regions,
thereby leading to an underestimated incidence rate.
However, as the cost of MS treatment is wholly subsi-
dised by the country's National Health Service, patients
are required to be registered at the health centres in
their respective residential areas. This raises the possibil-
ity that untreated new MS patients might not be covered
by the study. All the above-mentioned factors point to
an underestimation of the incidence rate. On the other
hand, a few incident cases recorded in the 1998–2007period might have actually experienced disease onset be-
forehand, if vague or poorly-defined first MS symptoms
had been overlooked at a time when access to MRI was
limited. The strengths of our study reside in its use of
the more sensitive McDonald MS diagnostic criteria vali-
dated by a neurologist specialised in MS, the use of CRC
methods to assess the meaning and significance of inci-
dence rates calculated by standard methods, and the pri-
ority given to avoiding the effects of changing health
care policies by limiting the study period to 1998–2007.
Conclusions
MS incidence in the Northern Lisbon population is simi-
lar to or moderately lower than that in other European
populations. CRM, subject to assessment of data-source
dependency and applied to patient or population sam-
ples, may constitute a potentially useful tool for assess-
ment of the accuracy of case-finding.
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